Drug response to PD-1/PD-L1 blockade: based on biomarkers

References

• SalmaninejadAKhoramshahiVAzaniAPD-1 and cancer: molecular mechanisms and polymorphismsImmunogenetics2018702738628642997
   PubMed Web of Science ®Google Scholar
• PooleRMPembrolizumab: first global approvalDrugs201474161973198125331768
   PubMed Web of Science ®Google Scholar
• SulJBlumenthalGMJiangXHeKKeeganPPazdurRFDA Approval Summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1Oncologist201621564365027026676
   PubMed Web of Science ®Google Scholar
• Pai-ScherfLBlumenthalGMLiHFDA Approval Summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyondOncologist201722111392139928835513
   PubMed Web of Science ®Google Scholar
• LiHYuJLiuCTime dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseJ Pharmacokinet Pharmacodyn201744540341428573468
   PubMed Web of Science ®Google Scholar
• LarkinsEBlumenthalGMYuanWFDA Approval Summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyOncologist201722787387828533473
   PubMed Web of Science ®Google Scholar
• [No authors listed]Three drugs approved for urothelial carcinoma by FDACancer Discov20177765966028546286
   PubMed Web of Science ®Google Scholar
• ShengJSrivastavaSSanghaviKClinical pharmacology considerations for the development of immune checkpoint inhibitorsJ Clin Pharmacol201757suppl 10S26S4228921644
   PubMed Web of Science ®Google Scholar
• KazandjianDSuzmanDLBlumenthalGFDA Approval Summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapyOncologist201621563464226984449
   PubMed Web of Science ®Google Scholar
• WeinstockCKhozinSSuzmanDU.S. Food and Drug Administration Approval Summary: atezolizumab for metastatic non-small cell lung cancerClin Cancer Res201723164534453928611199
   PubMed Web of Science ®Google Scholar
• NingYMSuzmanDMaherVEFDA Approval Summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapyOncologist201722674374928424325
   PubMed Web of Science ®Google Scholar
• [No authors listed]Nod for atezolizumab in advanced bladder cancerCancer Discov201776OF4
   Google Scholar
• ChoyMPharmaceutical approval updateP T201742636637128579722
   PubMedGoogle Scholar
• KaufmanHLRussellJHamidOAvelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialLancet Oncol201617101374138527592805
   PubMed Web of Science ®Google Scholar
• SyedYYDurvalumab: first global approvalDrugs201777121369137628643244
   PubMed Web of Science ®Google Scholar
• IkedaSOkamotoTOkanoSPD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancerJ Thorac Oncol2016111627126762740
   PubMed Web of Science ®Google Scholar
• BudcziesJMechtersheimerGDenkertCPD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcomaOncoimmunology201763e127977728405504
   PubMed Web of Science ®Google Scholar
• ClaveSPijuanLCasadevallDCD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patientsHistopathology201872225926928795418
   PubMed Web of Science ®Google Scholar
• Giroux LeprieurEDumenilCJulieCImmunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challengesEur J Cancer201778162328407528
   PubMed Web of Science ®Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib studyJ Clin Oncol201735192117212428375787
   PubMed Web of Science ®Google Scholar
• ChowLQHaddadRGuptaSAntitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohortJ Clin Oncol201634323838384527646946
   PubMed Web of Science ®Google Scholar
• Maleki VarekiSGarrigosCDuranIBiomarkers of response to PD-1/PD-L1 inhibitionCrit Rev Oncol Hematol201711611612428693793
   PubMed Web of Science ®Google Scholar
• BalarAVCastellanoDO’donnellPHFirst-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyLancet Oncol201718111483149228967485
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multi-centre, single-arm, phase 2 trialLancet Oncol201718331232228131785
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• SrinivasanSClementsJABatraJSingle nucleotide polymorphisms in clinics: fantasy or reality for cancer?Crit Rev Clin Lab Sci2016531293926398894
   PubMed Web of Science ®Google Scholar
• LeeSYJungDKChoiJEFunctional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancerGene2017599283527838455
   PubMed Web of Science ®Google Scholar
• YeoMKChoiSYSeongIOSuhKSKimJMKimKHAssociation of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinomaHum Pathol20176810311128851662
   PubMed Web of Science ®Google Scholar
• SeetharamuNPreeshagulIRSullivanKMNew PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumabLung Cancer (Auckl)20178677828761384
   PubMed Web of Science ®Google Scholar
• NomizoTOzasaHTsujiTClinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patientsSci Rep201774512428332580
   PubMed Web of Science ®Google Scholar
• [No authors listed]First tissue-agnostic drug approval issuedCancer Discov201777656
   Web of Science ®Google Scholar
• GelsominoFBarboliniMSpallanzaniAPuglieseGCascinuSThe evolving role of microsatellite instability in colorectal cancer: a reviewCancer Treat Rev201651192627838401
   PubMed Web of Science ®Google Scholar
• DudleyJCLinMTLeDTEshlemanJRMicrosatellite instability as a biomarker for PD-1 blockadeClin Cancer Res201622481382026880610
   PubMed Web of Science ®Google Scholar
• OvermanMJMcdermottRLeachJLNivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyLancet Oncol20171891182119128734759
   PubMed Web of Science ®Google Scholar
• GongJWangCLeePPChuPFakihMResponse to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutationJ Natl Compr Canc Netw201715214214728188185
   PubMed Web of Science ®Google Scholar
• MehnertJMPandaAZhongHImmune activation and response to pembrolizumab in POLE-mutant endometrial cancerJ Clin Invest201612662334234027159395
   PubMed Web of Science ®Google Scholar
• SantinADBelloneSBuzaNRegression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumabClin Cancer Res201622235682568727486176
   PubMed Web of Science ®Google Scholar
• Garcia-DiazAShinDSMorenoBHInterferon receptor signaling pathways regulating PD-L1 and PD-L2 expressionCell Rep20171961189120128494868
   PubMed Web of Science ®Google Scholar
• BellucciRMartinABommaritoDInterferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expressionOncoimmunology201546e100882426155422
   PubMed Web of Science ®Google Scholar
• ShinDSZaretskyJMEscuin-OrdinasHPrimary resistance to PD-1 blockade mediated by JAK1/2 mutationsCancer Discov20177218820127903500
   PubMed Web of Science ®Google Scholar
• ZaretskyJMGarcia-DiazAShinDSMutations associated with acquired resistance to PD-1 blockade in melanomaN Engl J Med2016375981982927433843
   PubMed Web of Science ®Google Scholar
• DongLQShiYMaLJSpatial and temporal clonal evolution of intrahepatic cholangiocarcinomaJ Hepatol Epub2018316
   Web of Science ®Google Scholar
• LiJYanSLiuZMultiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagusCancer Res201878233834728972077
   PubMed Web of Science ®Google Scholar
• SchmidtFEfferthTTumor heterogeneity, single-cell sequencing, and drug resistancePharmaceuticals (Basel)201692E3327322289
   PubMedGoogle Scholar
• LiRZhouMYueCMultiple single cell screening and DNA MDA amplification chip for oncogenic mutation profilingLab Chip201818572373429360118
   PubMed Web of Science ®Google Scholar
• VilainREMenziesAMWilmottJSDynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanomaClin Cancer Res201723175024503328512174
   PubMed Web of Science ®Google Scholar
• DasMZhuCKuchrooVKTim-3 and its role in regulating anti-tumor immunityImmunol Rev201727619711128258697
   PubMed Web of Science ®Google Scholar
• KoyamaSAkbayEALiYYAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsNat Commun201671050126883990
   PubMed Web of Science ®Google Scholar
• ShayanGSrivastavaRLiJSchmittNKaneLPFerrisRLAdaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancerOncoimmunology201761e126177928197389
   PubMed Web of Science ®Google Scholar
• HamiltonGRathBAvelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicityExpert Opin Biol Ther201717451552328274143
   PubMed Web of Science ®Google Scholar
• DonahueRNLeponeLMGrengaIAnalyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibodyJ Immunother Cancer201752028239472
   PubMed Web of Science ®Google Scholar
• HuangACPostowMAOrlowskiRJT-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature20175457652606528397821
   PubMed Web of Science ®Google Scholar
• SalemMLEl-BadawyAProgrammed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapyWorld J Hepatol20157232449245826483866
   PubMed Web of Science ®Google Scholar
• JinZYoonHHThe promise of PD-1 inhibitors in gastroesophageal cancers: microsatellite instability vs. PD-L1J Gastrointest Oncol20167577178827747091
   PubMed Web of Science ®Google Scholar
• GoodmanAPatelSPKurzrockRPD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomasNat Rev Clin Oncol201714420322027805626
   PubMed Web of Science ®Google Scholar
• WherryEJKurachiMMolecular and cellular insights into T cell exhaustionNat Rev Immunol201515848649926205583
   PubMed Web of Science ®Google Scholar
• DavarDWilsonMPrucknerCKirkwoodJMPD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIVCase Rep Oncol Med2015201573738926448890
   PubMed Web of Science ®Google Scholar
• KwongYLChanTSYTanDPD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginaseBlood2017129172437244228188133
   PubMed Web of Science ®Google Scholar
• GhoneimHEFanYMoustakiADe novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenationCell20171701142.e19157.e1928648661
   PubMed Web of Science ®Google Scholar